From this rationale it follows that the controlled increase in blood prolactin levels at physiological levels or inducing mild hyperprolactinemia, using dopamine antagonists, could stimulate innate and adaptive immunity and increase the survival of patients in certain critical situations, among which can be found patients infected with SARS-CoV-2. This evidence concerns the gene PRL and hyperprolactinemia.